Physician profile
William Burrow
NPI 1750395489
$8,000.20
in general payments reported to CMS, 2019-2025
32 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $634 · 2021: $1,018 · 2022: $1,421 · 2023: $1,452 · 2024: $1,022 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,717 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,716.92 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,823.46 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,538.51 | 2019-2025 | |
| Janssen Biotech, INC. | $849.42 | 2020-2025 | Tremfya |
| Lilly USA, LLC | $524.87 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.38 | 2022-2023 | Spevigo |
| Almirall LLC | $235.12 | 2019-2025 | Klisyri, Seysara |
| Incyte Corporation | $224.40 | 2021-2025 | Opzelura, Opzelura |
| Mayne Pharma Commercial LLC | $216.29 | 2019-2025 | |
| Ucb, INC. | $207.76 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $203.78 | 2023-2025 | Anzupgo, Adbry |
| E.R. Squibb & Sons, L.L.C. | $201.93 | 2022-2025 | Sotyktu |
| Strata Skin Sciences, INC. | $179.74 | 2019-2023 | Xtrac |
| Mallinckrodt Hospital Products INC. | $179.29 | 2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $174.68 | 2024-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $154.26 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $137.85 | 2019-2025 | |
| Dermavant Sciences, INC. | $134.72 | 2023 | Vtama |
| Pfizer INC. | $134.60 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $123.54 | 2019-2020 | |
| Convatec INC. | $93.29 | 2024-2025 | |
| Biofrontera INC. | $63.77 | 2019-2025 | |
| Galderma Laboratories, L.P. | $57.59 | 2020-2025 | Nemluvio |
| Organon LLC | $40.01 | 2025 | Vtama |
| Celgene Corporation | $39.96 | 2019 | |
| Genentech USA, INC. | $29.09 | 2019 | |
| Arcutis Biotherapeutics, INC. | $22.78 | 2025 | Zoryve |
| Tempus Ai, INC | $19.43 | 2024 | |
| Integra Lifesciences Corporation | $18.95 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Journey Medical Corporation | $18.21 | 2021 | |
| Boston Scientific Corporation | $15.29 | 2022 | |
| Botanix Sb INC | $14.15 | 2025 | Sofdra |
| Mission Pharmacal Company | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Burrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.